Please use this identifier to cite or link to this item: https://doi.org/10.4103/0301-4738.128618
Title: Brachytherapy of intra ocular tumors using ′bARC I-125 Ocu-Prosta seeds′: An Indian experience
Authors: Khetan, V.
Gopal, L. 
Shanmugam, M.
Gupta, A.
Sharma, T.
Bhende, P.
Muthukumar, S.
Subramaniam, R.
Kuppuswamy, T.
Saxena, S.
Dash, A.
Keywords: ′BARC I-125 Ocu-Prosta seeds′
choroidal melanoma
ciliary body melanoma
Episcleral plaque brachytherapy
retinal angioma
retinoblastoma
vasoproliferative tumor
Issue Date: Feb-2014
Citation: Khetan, V., Gopal, L., Shanmugam, M., Gupta, A., Sharma, T., Bhende, P., Muthukumar, S., Subramaniam, R., Kuppuswamy, T., Saxena, S., Dash, A. (2014-02). Brachytherapy of intra ocular tumors using ′bARC I-125 Ocu-Prosta seeds′: An Indian experience. Indian Journal of Ophthalmology 62 (2) : 158-162. ScholarBank@NUS Repository. https://doi.org/10.4103/0301-4738.128618
Abstract: Aim: To report our experience of brachytherapy using ′BARC I-125 Ocu-Prosta seeds′ for the management of intraocular tumors with regard to tumor control, globe preservation visual outcome, and patient survival at Sankara Nethralaya, Chennai, India between September 2003 and May 2011. Materials and Methods: We reviewed records of 35 eyes of 35 patients who underwent ophthalmic brachytherapy between September 2003 and May 2011. Twenty-one cases had choroidal melanoma, nine had childhood retinoblastoma, two had adult-onset retinoblastoma, and there were one case each of vasoproliferative tumor, retinal angioma, and ciliary body melanoma. Brachytherapy was administered using a 15-or 20-mm gold plaque with or without a notch. Brachytherapy was the primary treatment modality in all tumors other than retinoblastoma, wherein brachytherapy was done post chemoreduction for residual tumor. Results: For choroidal melanomas, the mean radiation dose was 68.69 ± 15.07 (range, 47.72-94.2) Gy. The eye salvage rate was 13/20 (65%) and tumor control rate was 16/20 (80%) at an average follow-up of 24.43 ± 24.75 (range, 1.5-87.98) months. For retinoblastoma, the mean dose was 45.85 ± 3.90 (range, 39.51-50.92) Gy. The eye salvage rate and tumor control rate was 5/6 (83.3%) at an average follow-up of 38.36 ± 31.33 (range, 4.14-97.78) months. All eyes with retinoblastoma needed additional focal therapy for tumor control and eye salvage. Conclusion: The results of this retrospective study confirms that the use of ′BARC I-125 Ocu-Prosta seeds′ in episcleral plaques to treat intraocular tumors offers a viable option for the management of intraocular cancers.
Source Title: Indian Journal of Ophthalmology
URI: http://scholarbank.nus.edu.sg/handle/10635/125543
ISSN: 03014738
DOI: 10.4103/0301-4738.128618
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

2
checked on Sep 30, 2022

WEB OF SCIENCETM
Citations

3
checked on Sep 30, 2022

Page view(s)

131
checked on Sep 22, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.